Evidence map›Paper›PMID 39464070›Full record

ArticlebioRxiv : the preprint server for biology2024

Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer.

Tracess B Smalley, Angelo Nicolaci, Kim C Tran, Jameela Lokhandwala, Nina Obertopp, Jenet K Matlack, Robert E Miner, Michael N Teng, Shari Pilon-Thomas, Jennifer M Binning

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Tracess B SmalleyDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.ORCID 0000-0002-3295-7443
Angelo NicolaciDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Kim C TranDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.
Jameela LokhandwalaDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Nina ObertoppDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Jenet K MatlackDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Robert E MinerDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Michael N TengDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.
Shari Pilon-ThomasDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Jennifer M BinningDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.ORCID 0000-0001-5871-686X

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapyU01CA244100 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ENDERLING, HEIKO, PILON-THOMAS, SHARI · 2020 to 2025
$2.6M
Biophysical basis for enzyme mediated deglycation in protein repairR35GM143004 · NIGMS · H. LEE MOFFITT CANCER CTR & RES INST · PI BINNING, JENNIFER · 2021 to 2025
$2.2M
Dual E3 ligase function of TRIM25 in modulating innate immunityK99GM154063 · NIGMS · H. LEE MOFFITT CANCER CTR & RES INST · PI Tracess Smalley · 2024 to 2026
$224k
NCI NIH HHS P30 CA076292NCI NIH HHS U01 CA244100NIGMS NIH HHS K99 GM154063NIGMS NIH HHS R35 GM143004
6 · The paper itself

Abstract

Human Papilloma Virus (HPV)-related cancers are a global health burden, yet there are no targeted therapies available for chronically infected patients. The HPV protein E6 is essential for HPV-mediated tumorigenesis and immune evasion, making it an attractive target for antiviral drug development. In this study, we developed an E6-targeting Proteolysis Targeting Chimera (PROTAC) that inhibits the growth of HPV(+) tumors. To develop E6 antagonists, we generated a panel of nanobodies targeting E6 proteins derived from the oncogenic HPV16 subtype. The highest affinity E6 nanobody, A5, was fused to Von Hippel Lindau protein (VHL) to generate a PROTAC that degrades E6 (PROTAC

Identifiers

PMID39464070
PMCPMC11507957

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.